PPCB Stock Scheduled to Reverse Split on Monday, May 18th (NASDAQ:PPCB)

PPCB (NASDAQ:PPCB) shares are set to reverse split on the morning of Monday, May 18th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, May 17th.

PPCB Price Performance

NASDAQ:PPCB traded down $0.02 on Thursday, reaching $0.07. The stock had a trading volume of 3,387,197 shares, compared to its average volume of 2,939,186. The firm has a market cap of $1.16 million, a P/E ratio of -0.01 and a beta of 3.59. PPCB has a 1-year low of $0.07 and a 1-year high of $10.81. The stock’s fifty day simple moving average is $0.11.

PPCB (NASDAQ:PPCB) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.28) EPS for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of PPCB from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, PPCB currently has an average rating of “Sell”.

PPCB Company Profile

Propanc Biopharma, Inc is a healthcare company. It focuses on the development of cancer treatments for pancreatic, ovarian and colorectal cancer primarily in Australia. The Company’s products include PRP and PRP-DCM. Propanc Biopharma, Inc, formerly known as Propanc Health Group Corporation, is based in Camberwell, Australia.